{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-069748","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.700808+00:00","generated_at":"2026-05-24T01:01:57.126761+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025","bullets":["Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.","Basta receives $700k base salary, 70% target bonus, and initial option grant of 1,085,000 shares vesting over 4 years.","Basta also granted 360k stock-price-hurdle PSUs and 180k revenue-based PSUs (target) under new inducement plan.","Curran severance includes base salary through June 30, 2026, 2025 target bonus lump sum, COBRA, and accelerated vesting.","Board adopted 2025 Employment Inducement Incentive Award Plan reserving 2,500,000 shares without stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-069748","json":"https://secwatch.observer/filing/0001193125-25-069748.json","markdown":"https://secwatch.observer/filing/0001193125-25-069748.md","text":"https://secwatch.observer/filing/0001193125-25-069748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/d913876d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:01:57.126761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08c3c0237f","claim":"Terrie Curran resigned as President and Chief Executive Officer at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}]},{"claim_id":"f9fe0a5d5a","claim":"Steven Basta was appointed as Chief Executive Officer, President and Class I director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President and Class I director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}